A practical reference on melanotan-2: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
She befriends investor Jesse Bloom and secures him as a client by helping him seize control of healthcare startup Rican, undercutting Felim and contributing to Eric’s removal from the trading floor. Harper begins a relationship with new MD Daniel Van Deventer (DVD) and travels to Berlin to confront her estranged brother, who rebuffs her. When Pierpoint plans to fold London into New York, Harper engineers a survival bid with Eric to preserve a London office, getting DVD fired. After Jesse manipulates her into committing insider trading, Eric shields her by exposing her forged transcripts instead, getting her fired. In series 3, six weeks prior to the main events, Harper accompanies Yasmin on a cruise in Mallorca and helps cover up Charles Hanani’s drowning. In the present, Harper works at ethical fund FutureDawn, where she earns Petra Koenig’s trust during the tumultuous Lumi IPO by helping hedge her exposure; the two co-found their own firm, LeviathanAlpha, with backing from Otto Mostyn. Harper enlists Pierpoint as their broker to humiliate Eric and illegally plans a short of Pierpoint’s ESG-backed debt, using an unwitting Yasmin to obtain information. The betrayal damages their friendship. Harper ultimately abandons the short but partners with Otto months later to launch a new hedge fund focused on shorting corrupt firms they can control. She and Yasmin also reconcile. In series 4, Harper runs a short-only fund within Otto's asset management firm but grows frustrated with his tight oversight, later learning it is tied to his political interests.
Vitexin is an apigenin flavone glucoside, a chemical compound found in the passion flower, Vitex agnus-castus (chaste tree or chasteberry), in the Phyllostachys nigra bamboo leaves, in the pearl millet (Pennisetum millet), and in hawthorn.
==== Heliscope single molecule sequencing ==== Heliscope sequencing is a method of single-molecule sequencing developed by Helicos Biosciences. It uses DNA fragments with added poly-A tail adapters which are attached to the flow cell surface. The next steps involve extension-based sequencing with cyclic washes of the flow cell with fluorescently labeled nucleotides (one nucleotide type at a time, as with the Sanger method). The reads are performed by the Heliscope sequencer. The reads are short, averaging 35 bp. What made this technology especially novel was that it was the first of its class to sequence non-amplified DNA, thus preventing any read errors associated with amplification steps. In 2009 a human genome was sequenced using the Heliscope, however in 2012 the company went bankrupt.
Sources: en.wikipedia.org
== Detection in biological fluids == Phenazepam may be measured in blood or plasma by chromatographic methods. Blood phenazepam concentrations are typically less than 30 μg/L during therapeutic usage, but have frequently been in the 100–600 μg/L range in automotive vehicle operators arrested for impaired driving ability.
=== Modern era (20th and 21st centuries) === As time progresses and technology advances, there is a constant need for change in the approach researchers take in their studies. Tissue engineering has continued to evolve over centuries. Tissue engineers have the ability to remake many of the tissues in the body through the use of modern techniques such as microfabrication and three-dimensional bioprinting in conjunction with native tissue cells/stem cells. These advances have allowed researchers to generate new tissues in a much more efficient manner. For example, these techniques allow for more personalization which allow for better biocompatibility, decreased immune response, cellular integration, and longevity. There is no doubt that these techniques will continue to evolve, as we have continued to see microfabrication and bioprinting evolve over the past decade. In 1960, Wichterle and Lim were the first to publish experiments on hydrogels for biomedical applications by using them in contact lens construction. Work on the field developed slowly over the next two decades, but later found traction when hydrogels were repurposed for drug delivery. In 1984, Charles Hull developed bioprinting by converting a Hewlett-Packard inkjet printer into a device capable of depositing cells in 2D. Three dimensional printing (3D printing) is a type of additive manufacturing which has since found various applications in medical engineering, due to its high precision and efficiency.
=== Main === Erika Toda as Kazuko Hosoki, a woman who rises from poverty in postwar Japan to become a Ginza club owner and later a nationally famous fortune teller. Sairi Ito as Minori Uozumi, a young novelist and single mother hired to write a book about Kazuko's life.
Sources: en.wikipedia.org
As iced-tea mix As fermented mix without alcohol (vegetable or fruit juice) As a supplement for vegetable or fruit juices to intensify the sweet flavor, to increase the nutritional value, as well as to create a umami taste Light or dark hemp drink without alcohol similar to beer As a distilled hard liquor, such as hemp spirit As herb liqueur or bitter using alcohol and sugar in the production process As a mixer for alcoholic drinks such as cocktails As a brewing ingredient for hemp beer As a base for gluten-free beer Gluten-free hemp beer does not require malt or cereal mash and it is low in calories. Hemp as a close relative of hops provides the fine and bitter beer taste even without using any hops.
==== 2025 ==== UPF1 was found to decline significantly during cellular senescence. The findings suggest that the fall in UPF1 accelerates senescence by slowing down nonsense-mediated mRNA decay. The study was conducted by scientists at Chungnam National University, the Korea Research Institute of Bioscience and Biotechnology, the Korea Advanced Institute of Science and Technology, and the US National Institute on Aging. Scientists at the University of California, Berkeley managed to extend the lifespans of elderly male mice by 73% with a 14% increase in overall lifespan with the Alk5 inhibitor OT+A5i. Researchers at RWTH Aachen University discovered that four senolytic compounds – JQ1, RG7112, nutlin-3a, and AMG232 – can decrease epigenetic age in in vitro blood samples. Researchers at the University of Osaka discovered that the protein AP2A1 may regulate cellular senescence, finding that suppressing the protein in older cells reversed senescence and promoted rejuvenation, whereas overexpression of the protein in young cells advanced senescence. A study by scientists at University College London, Stanford University, Inserm, and the University of Helsinki found that accelerated aging in specific organs could be predictors for diseases across the entire body, not just those affecting that particular organ. A study at the University of Texas at Austin identified the exposure of osteocytes to senescent cells as a key driver of aging in bones.
Alvin America "Eric" Tao (Ken Leung) is a MD on Pierpoint’s CPS desk and one of the series’ protagonists. A longtime Pierpoint executive, Eric is brilliant, volatile, and ruthlessly pragmatic, frequently crossing ethical lines in pursuit of power. He takes Harper Stern on as a protégé, recognizing her ambition as a reflection of his own. Eric rose through the firm’s New York headquarters under the late MD Newman, remaining conflicted between admiration for Newman and the racism Newman directed at him. Eric is longtime friends with global head of FICC Bill Adler, whom he once hired and who later surpassed him in rank. He is married to Candice Allbright with two daughters, Lily and Lara. In series 1, Eric salvages a disastrous trade Harper executes and admits he knows she never graduated from college but does not care. His relationship with key client Felim Bichan collapses after Eric makes offensive remarks in front of Felim’s wife. When Harper fails to recover the account, Eric traps and berates her in a conference room, prompting Daria Greenock to push Harper to report him, leading to Eric’s firing. On reduction-in-force day, Adler convinces Harper to retract her complaint to reinstate Eric, resulting in Daria’s dismissal. In series 2, Eric briefly regains Felim as client, only to lose him permanently after Harper goes behind Eric's back to sell a controlling stake in healthcare startup Rican to Jesse Bloom, which Eric had promised to Felim. Adler confronts Eric over sustained underperformance, sidelines him from the trading floor, and relegates him to a marginal role.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.